Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco

PLoS ONE

Volumn 5, Issue 6, 2010, Pages

  Das, Moupali ^a,b   Chu, Priscilla Lee ^a   Santos, Glenn Milo ^a   Scheer, Susan ^a   Vittinghoff, Eric ^b   McFarland, Willi ^a,b   Colfax, Grant N ^a,b  

^a SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CALCULATION; COMMUNITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHESIS; INFECTION RISK; OUTCOME ASSESSMENT; POISSON DISTRIBUTION; RESOURCE ALLOCATION; RISK ASSESSMENT; SCREENING; SEXUAL TRANSMISSION; UNITED STATES; VIRUS INHIBITION; VIRUS LOAD; VIRUS TRANSMISSION;

HIV INFECTIONS; HUMANS; POPULATION SURVEILLANCE; SAN FRANCISCO; VIRAL LOAD;

EID: 77956057163     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011068     Document Type: Article

References (64)

1. Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, et al. (1999) Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med 341: 394-402.
2. (2008) HIV testing and prophylaxis to prevent mother-to-child transmission in the United States. Pediatrics 122: 1127-1134.
3. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, et al. (2002) Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 29: 484-494.
4. Dickover RE, Garratty EM, Herman SA, Sim MS, Plaeger S, et al. (1996) Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. Effect of maternal zidovudine treatment on viral load. Jama 275: 599-605.
5. Mofenson LM, Lambert JS, Stiehm ER, Bethel J, Meyer WA, 3rd, et al. (1999) Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med 341: 385-393.
6. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, et al. (2000) Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 342: 921-929.
7. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, et al. (2001) Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 357: 1149-1153.
8. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, et al. (2005) Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 191: 1403-1409.
9. Attia S, Egger M, Muller M, Zwahlen M, Low N (2009) Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. Aids 23: 1397-1404.
10. Sullivan P, Kayitenkore K, Chomba E, Karita E, Mwananyanda L, et al. Reduction of HIV Transmission Risk and High Risk Sex while Prescribed ART:Results from Discordant Couples in Rwanda and Zambia; 2009; Montreal, CA.
11. Reynolds S, Makumbi F, Kagaayi J, Nakigozi G, Galiwongo R, et al. ART Reduced the Rate of Sexual Transmission of HIV among HIV-discordant Couples in Rural Rakai. Uganda; 2009; Montreal, CA.
12. Lingappa J, Hughes J, Donnel D, Baeten J, JIMullins J, et al. HIV-1 plasma RNA and risk of HIV-1 transmission. 2009; Paris, France.
13. Fang CT, Hsu HM, Twu SJ, Chen MY, Chang YY, et al. (2004) Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis 190: 879-885.
14. Wood E, Kerr T, Marshall BD, Li K, Zhang R, et al. (2009) Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. Bmj 338: b1649.
15. Katz MH, Schwarcz SK, Kellogg TA, Klausner JD, Dilley JW, et al. (2002) Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am J Public Health 92: 388-394.
16. Bezemer D, de Wolf F, Boerlijst MC, van Sighem A, Hollingsworth TD, et al. (2008) A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy. Aids 22: 1071-1077.
17. Porco T, Martin JN, Page-Shafer K, Cheng A, Charlebois E, et al. (2004) Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. Aids 18: 81-88.
18. Salomon JA, Hogan DR (2008) Evaluating the impact of antiretroviral therapy on HIV transmission. Aids 22 Suppl 1: S149-159.
19. Wilson DP, Law MG, Grulich AE, Cooper DA, Kaldor JM (2008) Relation between HIV viral load and infectiousness: a model-based analysis. Lancet 372: 314-320.
20. Lima VD, Johnston K, Hogg RS, Levy AR, Harrigan PR, et al. (2008) Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis 198: 59-67.
21. McCormick AW, Walensky RP, Lipsitch M, Losina E, Hsu H, et al. (2007) The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. Clin Infect Dis 44: 1115-1122.
22. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG (2009) Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373: 48-57.
23. Hammer SM, Eron JJ, Jr., Reiss P, Schooley RT, Thompson MA, et al. (2008) Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. Jama 300: 555-570.
24. (2005) HIV prevalence, unrecognized infection, and HIV testing among men who have sex with men-five U.S. cities, June 2004-April 2005. MMWR Morb Mortal Wkly Rep 54: 597-601.
25. Das-Douglas M, Zetola NM, Klausner JD, Colfax GN (2008) Written informed consent and HIV testing rates: the San Francisco experience. Am J Public Health 98: 1544-1545; author reply 1545.
26. Zetola NM, Klausner JD, Katz MH (2009) Simplifying consent increases hiv testing and new case detection: the san francisco experience. Am J Public Health 99: 1924.
27. San Francisco AIDS Office (2003) HIV/AIDS Epidemiology Annual Report 2002. San Francisco: San Francisco Department of Public Health. 31 p.
28. San Francisco AIDS Office (2006) HIV/AIDS Epidemiology Annual Report 2005. San Francisco: San Francisco Department of Public Health. 53 p.
29. HIV/AIDS Statistics and Epidemiology Section (2009) HIV/AIDS Epidemiology Annual Report 2008. San Francisco: San Francisco Department of Public Health.
30. Frieden TR, Das-Douglas M, Kellerman SE, Henning KJ (2005) Applying public health principles to the HIV epidemic. N Engl J Med 353: 2397-2402.
31. Truong HM, Kellogg T, Louie B, Klausner J, Dilley J, et al. (2009) Recent HIV-1 infection detection: comparison of incidence estimates derived by laboratory assays and repeat testing data. J Acquir Immune Defic Syndr 51: 502-505.
32. Zetola NM, Mintie A, Liska S, Wong E, Williams JD, et al. (2007) Performance of a transcription-mediated-amplification HIV-1 RNA assay in pooled specimens. J Clin Virol 40: 68-70.
33. Zetola NM, Grijalva CG, Gertler S, Hare CB, Kaplan B, et al. (2008) Simplifying consent for HIV testing is associated with an increase in HIV testing and case detection in highest risk groups, San Francisco January 2003-June 2007. PLoS ONE 3: e2591.
34. Ahrens K, Kent CK, Kohn RP, Nieri G, Reynolds A, et al. (2007) HIV partner notification outcomes for HIV-infected patients by duration of infection, San Francisco, 2004 to 2006. J Acquir Immune Defic Syndr 46: 479-484.
35. Marcus JL, Bernstein KT, Klausner JD (2009) Updated outcomes of partner notification for human immunodeficiency virus, San Francisco, 2004-2008. Aids 23: 1024-1026.
36. Zetola NM, Bernstein K, Ahrens K, Marcus JL, Philip S, et al. (2009) Using surveillance data to monitor entry into care of newly diagnosed HIV-infected persons: San Francisco, 2006-2007. BMC Public Health 9: 17.
37. MacKellar DA, Gallagher KM, Finlayson T, Sanchez T, Lansky A, et al. (2007) Surveillance of HIV risk and prevention behaviors of men who have sex with men-a national application of venue-based, time-space sampling. Public Health Rep 122 Suppl 1: 39-47.
38. Chu P, Hsu L, Schwarcz S (2008) Comparison of methods to measure completeness of HIV/AIDS reporting in San Francisco. XVII International AIDS Conference. Mexico City, Mexico.
39. Chen KT, Chang HL, Chen CT, Chen YA (2009) The changing face of the HIV epidemic in Taiwan: a new challenge for public health policy strategies. AIDS Patient Care STDS 23: 195-201.
40. Wand H, Wilson D, Yan P, Gonnermann A, McDonald A, et al. (2009) Characterizing trends in HIV infection among men who have sex with men in Australia by birth cohorts: results from a modified back-projection method. J Int AIDS Soc 12: 19.
41. Nakhaee F, Black D, Wand H, McDonald A, Law M (2009) Changes in mortality following HIV and AIDS and estimation of the number of people living with diagnosed HIV/AIDS in Australia, 1981-2003. Sex Health 6: 129-134.
42. Scheer S, Chin CS, Buckman A, McFarland W (2009) Estimation of HIV incidence in San Francisco. Aids 23: 533-534.
43. Hall HI, Song R, Rhodes P, Prejean J, An Q, et al. (2008) Estimation of HIV incidence in the United States. Jama 300: 520-529.
44. Karon JM, Song R, Brookmeyer R, Kaplan EH, Hall HI (2008) Estimating HIV incidence in the United States from HIV/AIDS surveillance data and biomarker HIV test results. Stat Med 27: 4617-4633.
45. Schafer JL (1999) Multiple imputation: a primer. Stat Methods Med Res 8: 3-15.
46. Zetola NM, Kaplan B, Dowling T, Jensen T, Louie B, et al. (2008) Prevalence and correlates of unknown HIV infection among patients seeking care in a public hospital emergency department. Public Health Rep 123 Suppl 3: 41-50.
47. Truong HH, Grant RM, McFarland W, Kellogg T, Kent C, et al. (2006) Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance. Aids 20: 2193-2197.
48. Arnold M, Hsu L, Pipkin S, McFarland W, Rutherford GW (2009) Race, place and AIDS: the role of socioeconomic context on racial disparities in treatment and survival in San Francisco. Soc Sci Med 69: 121-128.
49. Kellogg TA, Clements-Nolle K, Dilley J, Katz MH, McFarland W (2001) Incidence of human immunodeficiency virus among male-to-female transgendered persons in San Francisco. J Acquir Immune Defic Syndr 28: 380-384.
50. Krieger N (2003) Place, space, and health: GIS and epidemiology. Epidemiology 14: 384-385.
51. Krieger N (2006) A century of census tracts: health & the body politic (1906-2006). J Urban Health 83: 355-361.
52. Pilcher CD, Tien HC, Eron JJ, Jr., Vernazza PL, Leu SY, et al. (2004) Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis 189: 1785-1792.
53. Brenner BG, Roger M, Routy JP, Moisi D, Ntemgwa M, et al. (2007) High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 195: 951-959.
54. Coates TJ, Richter L, Caceres C (2008) Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet 372: 669-684.
55. Libamba E, Makombe S, Harries AD, Chimzizi R, Salaniponi FM, et al. (2005) Scaling up antiretroviral therapy in Africa: learning from tuberculosis control programmes-the case of Malawi. Int J Tuberc Lung Dis 9: 1062-1071.
56. Harries AD, Zachariah R, Jahn A, Schouten EJ, Kamoto K (2009) Scaling up antiretroviral therapy in Malawi-implications for managing other chronic diseases in resource-limited countries. J Acquir Immune Defic Syndr 52 Suppl 1: S14-16.
57. Frieden TR, Teklehaimanot A, Chideya S, Farmer P, Kim JY, et al. (2009) A road map to control malaria, tuberculosis, and human immunodeficiency virus/ AIDS. Arch Intern Med 169: 1650-1652.
58. Potts M, Halperin DT, Kirby D, Swidler A, Marseille E, et al. (2008) Public health. Reassessing HIV prevention. Science 320: 749-750.
59. De Cock KM, De Lay P (2008) HIV/AIDS estimates and the quest for universal access. Lancet 371: 2068-2070.
60. Castro A (2005) Adherence to antiretroviral therapy: merging the clinical and social course of AIDS. PLoS Med 2: e338.
61. Koenig SP, Leandre F, Farmer PE (2004) Scaling-up HIV treatment programmes in resource-limited settings: the rural Haiti experience. Aids 18 Suppl 3: S21-25.
62. Mukherjee JS, Ivers L, Leandre F, Farmer P, Behforouz H (2006) Antiretroviral Therapy in Resource-Poor Settings: Decreasing Barriers to Access and Promoting Adherence. J Acquir Immune Defic Syndr 43 Suppl 1: S123-S126.
63. Kim JY, Farmer P (2006) AIDS in 2006-moving toward one world, one hope? N Engl J Med 355: 645-647.
64. (2009) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services.